Janssen-Cilag International gets European Commission nod for subcutaneous Rybrevant for advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma8 April 2025 11:30 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) for an extension...
European Commission approves Janssen-Cilag International Rybrevant, Lazcluze combo for first-line treatment of lung cancer Ruchika Sharma31 Dec 2024 11:30 AM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved a Type II...
JnJ gets USFDA nod for Rybrevant plus standard of care chemotherapy for lung cancer treatment Ruchika Sharma21 Sept 2024 4:00 PM ISTRaritan: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in...
JnJ chemotherapy free lung cancer treatment Rybrevant plus Lazcluze gets USFDA okay Ruchika Sharma21 Aug 2024 12:30 PM ISTNew Jersey: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) plus...
EMA Committee recommends Rybrevant in combo with chemotherapy for adult patients with lung cancer after failure of prior therapy Ruchika Sharma4 Aug 2024 11:00 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
JnJ submits application to USFDA for Subcutaneous amivantamab for patients with EGFR-mutated non-small cell lung cancer Ruchika Sharma19 Jun 2024 3:56 PM ISTRaratin: Johnson & Johnson has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...
JnJ gets positive CHMP opinion for Rybrevant, chemotherapy combo for first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations Ruchika Sharma28 April 2024 12:30 PM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
USFDA nod to JnJ for Rybrevant, Chemotherapy combo for lung cancer treatment Anshika Mishra4 March 2024 5:09 PM ISTJohnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
Health Bulletin 04/ March/ 2024 Anshika Mishra4 March 2024 4:44 PM ISTHere the top health news for the day :Lady hardinge medical college to introduce new DNB and FNB courses soon Bringing good news to the postgraduate...
Johnson and Johnson gets USFDA approval for Rybrevant, chemotherapy combo for lung cancer treatment Ruchika Sharma2 March 2024 2:33 PM ISTRaritan: Johnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
Janssen seeks EMA marketing nod for Lazertinib plus Rybrevant for EGFR-Mutated Non Small Cell Lung Cancer Ruchika Sharma25 Dec 2023 3:30 PM ISTBelgium: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a marketing authorisation application...
JnJ seeks USFDA nod for Rybrevant plus Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer Ruchika Sharma24 Dec 2023 12:30 PM ISTRaritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
